Giuliano Albergo
Research Subjects
Giuliano Albergo has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ginevra Lombardozzi
Clinica Neuropsichiatrica Villa Von Siebenthal, Via della Madonnina 1, 00040 Roma, Italy
1 shared publication - Giulio Verrienti
Department of Neurorehabilitation, Casa di Cura “Villa Verde”, 73100 Lecce, Italy; Department of Engineering for Innovation, University of Salento, 73100 Lecce, Italy
1 shared publication - Sergio De Filippis
Villa Von Siebenthal Neuropsychiatric Hospital and Clinic, Genzano di Roma, Rome, Italy
1 shared publication
Latest Publications
- 13 October 2025
- Published by Taylor & Francis in International Journal of Psychiatry in Clinical Practice
- Vol. 30 (1) , 12-22
Trazodone in neurology, a new life for an old molecule - an updated, comprehensive, systematic review of clinical trials
The triazolopyridine derivative trazodone is approved for the treatment of major depressive disorder (MDD) in adults; according to the available literature, this molecule, through a specific dose-dependent profile of action, was found to be a potential therapeutic option in some neurological conditions. This systematic review aimed to synthesise the available evidence on the use of trazodone in neurological patients. PubMed was searched for articles published from inception until March 2025. Article reference lists were screened, and relevant articles were retrieved for consultation. Clinical trials specifically investigating trazodone in neurological populations were included, following PRISMA guidelines for systematic reviews. Out of 69 records initially retrieved, 14 studies met the inclusion criteria, comprising 13 randomised controlled trials and 1 retrospective study, with a total of 608 patients. Most of the included studies focused on individuals with dementia, while others explored its use in different neurological disorders. Despite being an older antidepressant, trazodone remains widely prescribed. Beyond treating depression in neurological patients, it may may be useful in the treatment of some neurological aspects. However, current evidence remains limited. Further high-quality research is necessary to better define the therapeutic potential of trazodone in the management of neurological conditions.
- 13 October 2025
- Published by Taylor & Francis in International Journal of Psychiatry in Clinical Practice
- Vol. 30 (1) , 12-22
Trazodone in neurology, a new life for an old molecule - an updated, comprehensive, systematic review of clinical trials
The triazolopyridine derivative trazodone is approved for the treatment of major depressive disorder (MDD) in adults; according to the available literature, this molecule, through a specific dose-dependent profile of action, was found to be a potential therapeutic option in some neurological conditions. This systematic review aimed to synthesise the available evidence on the use of trazodone in neurological patients. PubMed was searched for articles published from inception until March 2025. Article reference lists were screened, and relevant articles were retrieved for consultation. Clinical trials specifically investigating trazodone in neurological populations were included, following PRISMA guidelines for systematic reviews. Out of 69 records initially retrieved, 14 studies met the inclusion criteria, comprising 13 randomised controlled trials and 1 retrospective study, with a total of 608 patients. Most of the included studies focused on individuals with dementia, while others explored its use in different neurological disorders. Despite being an older antidepressant, trazodone remains widely prescribed. Beyond treating depression in neurological patients, it may may be useful in the treatment of some neurological aspects. However, current evidence remains limited. Further high-quality research is necessary to better define the therapeutic potential of trazodone in the management of neurological conditions.